We have profiled, for the first time, an evolving human metastatic microenvironment, measuring gene expression, matrisome proteomics, cytokine and chemokine levels, cellularity, ECM organization and biomechanical properties, all on the same sample. Using biopsies of high-grade serous ovarian cancer (HGSOC) metastases that ranged from minimal to extensive disease, we show how non-malignant cell densities and cytokine networks evolve with disease progression. Multivariate integration of the different components allowed us to define for the first time, gene and protein profiles that predict extent of disease and tissue stiffness, whilst also revealing the complexity and dynamic nature of matrisome remodeling during development of metastases. Although we studied a single metastatic site from one human malignancy, a pattern of expression of 22 matrisome genes distinguished patients with a shorter overall survival in ovarian and twelve other primary solid cancers, suggesting that there may be a common matrix response to human cancer.
Introduction
Solid tumors consist of malignant cells surrounded and infiltrated by a variety of host cells that are recruited and 'corrupted' by the cancer, aiding its growth and spread (1, 2) . A dynamic network of soluble factors, cytokines, chemokines, growth factors and adhesion molecules drive the interactions between malignant and non-malignant cells to create this tumor microenvironment (TME) (3, 4) . The TME network stimulates extracellular matrix (ECM) remodeling, expansion of abnormal vascular and lymphatic networks and migration of cells into and out of the tumor mass (5, 6) . Solid tumors are also typically stiffer than the surrounding tissue due to aberrant ECM deposition and organization that has a major influence on cell and tissue mechanics (7, 8) .
While the TME is of critical importance during initiation and spread of cancer, relatively little is known about its evolution or the relationship between the molecular mechanisms of disease progression and higher-order features such as the extent of disease, non-malignant cell density and tissue stiffness. Studies on molecular mechanisms of human cancer have mainly focused on large-scale genomic and transcriptomic analysis of primary tumors (9) and the immune cell landscape (1) . Human cancer evolution is also now being studied in multiple metastatic sites e.g. (10, 11) but mainly in terms of the genomics of the malignant cells. Also, most of these analyses focus on one stage of a cancer.
Here, for the first time, we have used multi-layered TME profiling of a metastatic site, omental metastases of high-grade serous ovarian cancer (HGSOC), to identify molecular changes that predict the higher-order TME features. Our study differs from other genomic and transcriptomic studies in two important ways: first, we have integrated data from six different TME parameters from each metastatic sample studied and second, we have studied the evolution of metastases by including samples that vary in the extent of disease.
HGSOC is one of the most lethal of the peritoneal cancers: less than 30% of patients currently survive more than five years after diagnosis with little improvement in overall survival in the past 40 years (12) . As poor prognosis is mainly due to early dissemination into the peritoneal cavity (12, 13) and HGSOC metastases have a complex TME (14) , there is a need for an integrated understanding of its different components (12) . We chose to study the omental TME because it is the most frequent site for HGSOC metastases and is routinely resected during debulking surgery.
Using samples ranging from minimal to extensive disease we conducted cellular, biomechanical and molecular analyses on each biopsy. Integration of the different components using multivariate analyses allowed us to define for the first time, gene and protein profiles that predicted extent of disease and tissue stiffness whilst also revealing how the ECM is remodeled during metastases development. Of particular interest was an ECMassociated molecular signature, that we termed the matrix index, that predicted both extent of disease and tissue stiffness in our sample set. This novel signature distinguished patients with shorter overall survival not only in ovarian cancer, but also in twelve other cancer types irrespective of patient age, stage or response to primary treatment, suggesting a common matrix response to human primary and metastatic cancers.
Results

Study Design
We analysed six different parameters of omental biopsies from 36 HGSOC patients: the extent of disease, densities of non-malignant cells, tissue mechanics, cytokines, matrisome protein and RNA profiles ( Figure 1A ). The samples ranged from uninvolved or minimallydiseased omentum to biopsies with extensive disease (Table S1 , Figure 1B and Figure S1A ).
The extent of disease in each biopsy was measured by digital histopathology on haematoxylin and eosin (H&E) stained sections and was calculated as the percentage of tissue area occupied by malignant cells and stroma. We termed this the 'disease score'. Remodeling of the omentum was extensive when malignant cells were present and the malignant cells comprised a minor proportion of the tissue ( Figure 1B ). In order to monitor for any significant changes in sample architecture during tissue processing for the different analyses we took serial sections for H&E staining. We did not observe any major changes in disease score between the different areas analyzed.
The density of the major non-malignant cell populations was measured by immunohistochemistry (IHC) and digital histopathology in the same specimens. The biomechanical properties of the tissues were measured using a mechanical indentation methodology (15) that gave us the tissue modulus of each sample.
Twenty-nine cytokine and chemokines were measured in protein lysates using an electrochemiluminescence assay (Table S2 ). For proteomic analysis of the same biopsies we focused on the ECM and associated molecules using a method that enriches whole tissue lysates for the matrisome protein compartment (16) . Using this technique we detected 145 proteins (Table S3 ). The term 'matrisome' is defined as the ensemble of all core ECM proteins (collagens, proteoglycans, glycoproteins) and associated molecules (the secretome, ECM-regulators and ECM-affiliated molecules) of tissue extracellular matrices (17). After alignment and filtering, RNA sequencing identified 15,441 protein-coding genes (Table S4) .
We then used univariate analyses and a multivariate regression method -partial least squares (PLS) (18) -to model the relationships between these different components of the metastases ( Figure 1C) .
The relationship between cell density and disease score
Using a tissue microarray constructed from the biopsies we quantified the adipocytes, fibroblasts and leukocytes which were the major non-malignant components in the specimens and related this to disease score. The area occupied by adipocytes, the major cell type of the normal omentum, decreased with disease score ( Figure 1B ) and this was in part due to a reduction in the diameter of the adipocytes (Figure 2A ) which may reflect research showing that adipocytes can provide energy for ovarian cancer cell growth (13) . Using α-smooth muscle actin (-SMA) and α-fibroblast activation protein (α-FAP) as markers of cancerassociated fibroblasts (CAFs) (19), we assessed the area of the tissue occupied by -SMA+ and α-FAP+ cells and found a strong positive correlation with disease score for both markers
We then stained and counted six major leukocyte subtypes and plotted cell density against disease score. In all cases there was a significant positive correlation between leukocyte density and disease score (p<0.001) ( Figure 2D , Figure S1B ). Densities of T cells with the surface markers CD3, CD4, CD8 and CD45RO strongly correlated with each other (p<0.001, r>0.6) but CD68+ macrophage density only weakly correlated with the other leukocytes (p<0.05, r<0.5) ( Figure 2E , Table S5 ).
Therefore, as metastases developed in the omentum, the fatty tissue was replaced by a combination of fibroblasts, lymphocytes and macrophages. The cellular composition that we observed illustrates the changes from a normal omental tissue, primarily composed of adipocytes with minimal immune cell infiltrate and little fibroblastic reaction, to heavily diseased tissues with profound tumor-associated inflammation and a large increase in all types of leukocytes and fibroblasts. However, whilst there was a general increase in stromal cell density across all of the markers we studied, we observed larger variance with high disease score samples for all immune cell counts. This is to be expected as it is already welldocumented that the TME of advanced HGSOC biopsies ranges from sparse to dense leukocyte infiltration.
The immune cell densities significantly correlated with their corresponding immune gene expression signatures extracted from the associated RNAseq data for each sample (Table S6) and levels of the adipogenic transcription factor PPAR mRNA declined with disease score ( Figure S1C) . Thus, the cell density scores were validated by the gene transcription data.
Leukocyte density and cytokine networks in the TME
Next, we correlated leukocyte density against levels of 29 different cytokines and chemokines in protein lysates of the metastases. There were eight significant correlations (Figure 2F, Table S7 ), the strongest of which was, unexpectedly, an association between IL16, a chemoattractant and modulator of T cell function, and the density of CD3, CD45RO and CD8 cells. These correlations became stronger with the 10 samples with the highest disease score ( Figure S1D ). IHC revealed IL16 protein in both malignant and stromal areas, with a higher density in the former ( Figure 2G ). There was also a high positive correlation between global cell proliferation assessed by Ki67 and LTA, IL17A, IL15, CXCL10 ( Figure   2F ).
As cytokine networks are major determinants of leukocyte density and phenotype in the TME (3, 20) , we asked if the cytokine proteins and genes we detected in the tissue lysates could inform us about the networks that regulate omental metastases. We constructed heatmaps showing pairwise comparisons of cytokine protein and gene transcription levels ( Figure 2H , Figure S1E , Tables S8 and S9 ). Overall the protein gene correlation was 30%, in line with other studies e.g. (21). The heatmaps show five significant co-expressions at both gene and protein level: IL6 with IL1A, IL1B, and IL8, CSF2 with IL8, and CCL4 with CCL3. IL6 was of particular interest as we previously identified this as a major mediator of cytokine networks in ovarian cancer (20, 22) . Finally, we asked if levels of any of the cytokines and chemokines associated with disease score. There were weak but significant associations with disease score with IL12B, IL13, IL16, VEGF, CCLs 11, 26, and CXCL10.
These results suggest that malignant cell-derived cytokine and chemokine networks in the omental metastases regulate leukocyte density and overall proliferative index. Unexpectedly, we identified the CD4 ligand IL16 as a potential major mediator of the leukocyte infiltrate. It is interesting that increased tissue and serum levels of IL16 have been reported during tumor development in laying hen models of ovarian cancer and in ovarian cancer patients (23).
These cytokine and cellularity data confirm and extend previous research on the ovarian cancer and other tumor microenvironments and we believe validate our approach. Extensive study of another TME component, the matrisome, has recently become possible through proteomics methods that focus on these proteins (17). There is currently little information on how the matrisome evolves with disease progression. Therefore, our next aim was to study the ECM-associated proteins and genes, collectively termed the matrisome, in the same biopsies.
How the matrisome changes with disease progression
Using our matrisome-focused proteomic technique (16) and the RNAseq data we quantitatively assessed matrisome proteins and genes. In terms of relative mass ratios, the major matrix proteins in samples with the lowest disease score were collagen 1, 6 and 3, the glycoprotein fibrillin, the ECM regulator alpha-2-macroprotein, and the basement membrane proteoglycans lumican and heparin sulphate proteoglycan-2. In contrast, biopsies with the highest disease score had an expansion of ECM-glycoproteins fibrinogen and fibronectin, as well as increases in proteoglycans, secreted factors, and affiliated proteins, (FDR <0.1) ( Figure 3A ).
Extending the analysis to the entire sample set we found that as disease score increased levels of some matrisome proteins decreased and others increased. Comparing the relative mass ratio of all matrisome proteins with disease score, we found that 18 proteins decreased and 49 proteins increased with disease progression ( Figure 3B , Table S10 ). After these univariate analyses, we used the multivariate regression PLS method to rank genes and proteins according to their influence on disease score, and a permutation-derived threshold was applied to determine those that were most strongly associated with disease score (24,25).
Of these, 58 proteins ranked top in PLS modeling of disease score (r 2 = 0.70), defining a matrisome protein signature of disease score ( Figure 3C , Table S11 ).
412 of the 764 matrisome genes detected in our transcriptomics dataset also predicted disease score (Table S12 ). The top 60 genes are shown in Figure 3D with 27 ECM-associated molecules predicting disease score at both the gene and protein level ( Figure 3E , Figure   S2A ). We used IHC to detect four of these proteins, FN1, COMP, CTSB and COL11A1, in HGSOC omentum detecting all four within stromal regions ( Figure 3F ). As collagen organisation strongly influences cell behavior and tissue mechanics (26,27), we utilised twophoton microscopy to visualise collagen fibres using second harmonic generation (SHG) label-free illumination ( Figure 3G ). In low disease score tissues collagen fibres were thin and arranged mostly around the adipocytes. In high disease score tissues, there were denser arrays of long collagen bundles with an apparent micro-scale orientation preference. Collagen orientation correlated strongly with disease score ( Figure 3G ). It should be noted that Figure   3A shows relative matrisome protein abundance as mass ratios whereas Figure 3G depicts the alignment of collagen in the tissues. While the amount of collagen does increase in diseased tissue, its relative abundance goes down as other matrisome proteins are induced as the tissue becomes more diseased. Representative images for COL1A1 IHC staining are shown in Figure S2B .
Other biological processes associated with disease score
We then analysed the RNAseq data to find other biological processes associated with disease score (Table S13 ). Significantly associated pathways included cell metabolism, adhesion, communication as well as ECM organization and immune response pathways ( Figure S2C , Table S14 ).
We have described here, for the first time, how the matrisome changes with disease progression. As some of the strongest correlations with disease score were found with these ECM-associated proteins and genes, and increased tissue stiffness has been linked with tumor progression (28,29), we next investigated how the changes in matrisome genes and proteins related to the biomechanical properties of the biopsies.
Relationships between tissue modulus (stiffness) and disease score
We used mechanical indentation (15) to determine tissue modulus (which describes material stiffness independent of sample size) and the stress-relaxation behavior of the samples. We measured disease score from histological sections of the area of the specimen that was indented ( Figure 4A , Figure S3 ). Biopsies with a high disease score displayed a non-linear loading response and greater stress relaxation while there was a relatively linear loading response in low disease score tissue ( Figure 4B , Figure S3C , Table S15 ). Tissue modulus values in high disease score biopsies were one-two orders of magnitude higher than in low disease biopsies. There were significant positive correlations between tissue modulus and malignant cell area, the stromal area and disease score of each biopsy ( Figure 4C , Figure   S3D ). Thus, there was a significant log relationship between tissue modulus and disease score in the evolving TME suggesting a close association of tissue stiffness with disease progression.
The matrisome, tissue stiffness and disease score
Using the PLS method, we identified 64 matrisome proteins, mainly glycoproteins, that accurately predicted tissue modulus (r 2 = 0.69) ( Figure 4D , Figure S4A , Table S16 ). We then used 764 matrisome genes detected by RNAseq and identified 405 that predicted tissue modulus ( Figure 4E , Figure S4B , Table S17 ) of which 38 also featured as proteins in Figure   4D . Thus, as with disease score, the tissue modulus could be predicted by a subset of ECMassociated genes and proteins of the matrisome.
We also modeled tissue modulus against the entire transcriptome of the metastases ( Figure   S4C , Table S18 ). Genes associated with cell metabolism, cell communication, wound healing, ECM organization, as well as development, correlated with tissue modulus ( Figure   S4D , Table S19 ). Figure 4F shows the PLS prediction plot and the top 50 genes from this signature. As expected there was a strong overlap with disease score-associated genes and proteins (74% and 75% respectively) and these were significantly associated with tissue modulus (Table S20) . Collectively, the experiments described above demonstrated the complexity and dynamic nature of matrisome evolution during development of HGSOC metastases and the close relationship between tissue stiffness and extent of disease.
A subset of matrisome molecules models both disease score and tissue modulus and has prognostic significance in HGSOC
We next asked how many matrisome genes and proteins significantly defined both disease score and tissue modulus in our sample set ( Figure 5A , Table S21 ). Twenty-two molecules were highly significant across all of our analyses with a gene:protein concordance of 68%
( Figure 5A , Figure S5A ). Thirteen of the 22 proteins had documented protein:protein interactions ( Figure 5B ). Using the ChEA database (30) we found that the 22 genes shared a range of common transcription factors including RUNX2, STAT3, SMAD4, WT1, JUN and TP53. These reflect pathways associated with Wnt signalling pathway, inflammation and osteogenesis, whilst TP53 is of course the most frequently mutated gene in HGSOC, a major genetic driver of the disease ( Figure S5B and Table S22 ).
Using these 22 most significant molecules, we measured the ratio between the mean expression levels of the positively regulated genes and the mean expression levels of the negatively regulated genes. We termed this the matrix index because these molecules are all components of the matrisome (17). As would be expected, the matrix index of each sample significantly correlated with disease score and tissue modulus in our set of samples (p<0.0001) as would be expected ( Figure 5C ). There were also significant positive and negative correlations between matrix index and immune cell signatures in the corresponding RNAseq data ( Figure 5D , Table S23 ), notably Treg and Th2 cell signatures, cell subtypes associated with tumor promotion and immune suppression (31) and a modest statistically significant relationship between disease score and entropy as a measure of clonal abundance for T and B cells (Table S23 ). These data suggest that matrix index molecules may influence expansion of specific infiltrating cell populations. In support of these findings, there were significant linear correlations between the matrix index and the data in Figure 
Relevance of matrix index to other stages of HGSOC and prognosis
As the matrix index positively correlated with disease score, tissue modulus and immunesuppressive signatures in our sample set, we wondered if it would distinguish ovarian cancer patients with a poorer prognosis in transcriptomic data from untreated primary tumors. We extracted expression values from two publicly available HGSOC gene expression datasets and calculated the matrix index for each sample. The high and low matrix index groups were determined using a method described previously (32). High matrix index significantly correlated with shorter overall HGSOC patient survival in both the ICGC and TCGA gene expression datasets, as well as in our original sample set ( Figure 5E , Figure S5B -E). To test that the clinical outcome association of the matrix index was not a random finding we conducted 200,000 simulations and found that the association was significantly above that expected from random signatures.
In order to account for the higher relative abundance of tumor cells compared with stroma present in the TCGA ovarian cancer samples compared to our samples, we plotted the correlation between matrix index and % tumor cell or % stroma in each TCGA sample. In both cases we observed no association with matrix index ( Figure S5F ). Taken together with the immune cell correlations, this further suggests the matrix index is not only a measure of the tissue remodeling that accompanies HGSOC, but is also a measure of a matrisome composition that better supports tumor progression. ( Figure 5F , left panel). However, using multivariate analysis, matrix index was the single significant predictor of ovarian cancer survival independently of age, stage, grade and treatment outcome ( Figure 5F , right panel and Table S24) .
At the protein level, we used matrix index to examine the recently released TCGA/CPTAC ovarian cancer proteomics dataset. Whilst the study was not focused on detecting ECM proteins, which requires matrisome protein enrichment prior to analysis, as described above, we found that there were 12 proteins from the matrix index with a significant association with survival (10 with p < 0.05 and a further 2 with p < 0.1).
Matrix Index in other human cancers
ECM remodeling is a common feature of many human cancers and significant desmoplasia and ECM deposition is found in other solid tumors. Since we hypothesize that the matrix index is a measure of a tumor-promoting matrisome in HGSOC, we wondered if it may also be a feature associated with poor outcome in other cancer types. We calculated matrix index values in 30 other publicly available gene expression datasets from epithelial, mesenchymal and haematologic malignancies analysing data from 9215 human cancer biopsies. High matrix index was an indicator of poor prognosis in epithelial and mesenchymal cancers but not in haematological cancers, melanoma and glioblastoma ( Figure 6A and Figure S6A ).
Using univariate analysis, high matrix index predicted shorter overall patient survival in 15 datasets representing 13 major cancer types (p < 0.05) ( Figure S6B , Table S25 ). The range of matrix index values across all these cancer databases had a median value close to 1.0 ( Figure   S6C ). We believe this provides further evidence that the pattern of ECM-associated gene expression determined by the matrix index may be a common feature of human cancers.
Remarkably, multivariate analysis showed that the prognostic value of the matrix index was independent of age, stage, grade and response to primary treatment in 15 of the datasets representing 13 major cancer types (p < 0.05) ( Figure 6B ).
Using IHC, we confirmed the presence of four of the upregulated matrix index proteins FN1, COL11A1, CTSB, and COMP, in three tissue microarrays from triple negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), and diffuse large B-cell lymphoma (DLBCL) ( Figure 6C ). These cancers reflected the range of hazard ratios for high matrix index in Figure 6B . Digital microscopy analysis showed the highest staining level in TNBC 
Data resource
All data in this paper are provided in a mine-able web-based resource http://www.canbuild.org.uk currently under construction. Users are able to download, visualize, analyse and integrate across datasets.
Discussion
In this paper we have profiled, for the first time, an evolving human metastatic microenvironment, using analysis that includes gene expression, matrix proteomics, cytokine/chemokine expression, ECM organization and biomechanical properties, all performed on the same sample. This gives a unique and informative snapshot of the evolving metastatic state of one type of ovarian cancer. Integration of the most significant features of this microenvironment may have identified a matrix response that is conserved in other cancers of epithelial or mesenchymal origins.
Our study has also shown that conducting multi-level analysis with data integration on wellcharacterized cancer biopsies with a range of disease involvement, and multiple analyses per sample, can identify important features representative of the evolving TME. This approach is complementary to 'omic' molecular cancer datasets that have larger numbers of samples. The data presented here provide a unique resource regarding molecular, cellular, and mechanical regulation in the tumor microenvironment and a template for bioengineers who are building complex tumor microenvironment models.
Molecular genetics has revealed great intra-and inter-tumor heterogeneity. It is now accepted that malignant cell clones undergo Darwinian evolution, resulting in a high level of molecular heterogeneity. In contrast, this study shows that the interactions between malignant cells and the host to remodel the tissue matrix may be more consistent. It is already known that high lymphocyte density is a common indicator of good prognosis at different stages of disease in many malignancies including HGSOC (14) . We suggest that another common feature of TMEs may be patterns of matrisome genes and proteins and that these also have prognostic significance.
The up-regulated genes that were most significantly related to disease score in our analysis, We have not focused on proteases in this study. However, in our samples, normal tissue ECM stained highly positive and evenly for COL1A1, but COL1A1 staining in diseased sections, whilst still strong, appeared more uneven. In particular there was reduced staining around malignant cell areas. This may be due to expression of proteases such as MMP13, which degrade collagen structures (50) , that we identified in our PLS analysis. Other matrix remodeling proteases that we identified such as MMP7, MMP11, CTSB, and ST14 are also able to degrade collagens, albeit to a lesser extent, but may also be capable of degrading matrix proteoglycans and glycoproteins (51, 52) . In addition to protease activity, the apparent reduction in COL1A1 by mass ratio ( Figure 3A ) was in part due to the relative increase in matrisome complexity in diseased tissues. Also, we used a modified matrisome analysis method which increased our protein detection coverage, at the cost of underestimating the absolute amount of large fibrous core matrisome proteins such as COL1A1.
As we have shown, there was a core group of matrisome molecules that best predicted tissue
modulus. This appears to be through an expansion of matrisome glycoproteins and proteoglycans ( Figure 3A ) and a reorganization of fibrillar collagens ( Figure 3G ). The expansion of the glycoprotein and proteoglycan compartment increases the potential for posttranslational modification within the extracellular space which could significantly alter the mechanical properties of the tissue, particularly through glycosylation and cross-linking (53).
For example, glycosaminoglycans on proteoglycans contribute to hydration, which contributes to tissue stiffness (54) . Additionally, specific ECM cross-linking molecules, including the pro-lysyl hydroxylases which cross-link matrix proteins through collagen-like peptides, were associated with increasing disease in our samples (55) . Molecules like COL11A1 and COMP are normally only present in stiffer tissues such as cartilage and bone, while VCAN plays a role in the morphogenesis of these stiffer tissues. In addition, collagens 11 and 6 play roles in collagen fibril organization and matrix integrity. There is a significant desmoplastic response in most solid tumors, but given that there is large intra-and inter-tumor heterogeneity it is important to understand why our index of matrisome gene expression defines patients with poor prognosis in multiple human cancers. The matrix index does not seem to be simply a measure of the amount of desmoplasia or stromal component that accompanies cancer growth. We believe that it is a measure of a type matrisome composition that is more able to promote tumor growth. We found a strong 
RNA isolation and sequencing
Total RNA was extracted from 10 x 50 μm cryosections from frozen tissue sections and placed directly into the RLT Plus buffer (Qiagen) and rigorously vortexed. Samples were then processed using Qiagen RNeasy Plus Micro kit according to manufacturer's instructions.
RNA quality was analyzed on agilent bioanalyzer 2100 using RNA PicoChips according to manufacturer's instructions. RNA integrity numbers (RIN) were between 8.1 and 9.9. RNASeq was performed by Oxford Gene Technology (Benbroke, UK) to ~42x mean depth on the Illumina HiSeq2500 platform, strand-specific, generating 101bp paired-end reads, as previously described (65). The detailed methods regarding RNA sequencing and bioinformatic analysis are provided in the Supplementary Methods.
Quantitative Proteomics
The 
Cytokine and chemokine analysis
Cytokine and chemokines were assayed using Mesoscale Discovery Platform (MSD SI2400) according to manufacturer's instructions. Cytokine panel 1(Human) K15050D, Proinflammatory panel 1(human) K0080087, and Chemokine panel 1(Human) K0080125
were used. Samples used were lysates from the ECM-enrichment protocol (described above).
The amount of total protein used from each sample was between 1 and 3 μg.
Mechanical characterization
Mechanical characterisation was performed on whole tissues using a flat-punch indentation methodology on an Instron ElectroPuls E1000 (Instron, UK) equipped with a 10 N load cell (resolution = 0.1 mN) in order to measure the modulus of the tissue samples(15)(Delaine-
Smith et al., 2016). The detailed method of quantification is provided in the Supplementary
Methods.
Histochemical analysis
Frozen tissues that were subsequently used for RNA, proteomics and cytokine analysis were cryosectioned to 8-10 µm slices. Sections were fixed in in 4 % paraformaldehyde (PFA) and stained with haematoxylin and eosin using standard methods. Tissues used in mechanical characterization were cut in half at the center of the tissue dye marked area and perpendicular to the direction of indentation while still frozen. Tissue was then fixed in 4 % PFA for 24 h and paraffin embedded and sectioned (8 µm) using standard procedures followed by H&E staining. All tissue sections were scanned using a 3DHISTECH Panoramic 250 digital slide scanner (3DHISTECH, Hungary) and the resulting scans were analysed using Definiens 
Statistical and bioinformatics analysis
All statistical analyses and graphics were performed in the statistical programming language R (version 3.1.3). Detailed methodology for PLS regression models, Matrix index and its clinical association across cancer types is provided in the Supplementary Methods.
Accession Numbers
RNA-Seq data have been deposited in Gene Expression Omnibus (GEO) under the accession number GSE71340. Proteomic data are available via the PRIDE database accession number PXD004060.
Data availability
All of the primary data are deposited at http://www.canbuild.org.uk.
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Higher order features
